SynthesisFrontiers in oncology2020
Clinical Efficacy of Immune Checkpoint Inhibitors in Older Non-small-Cell Lung Cancer Patients: A Meta-Analysis.
Synthesis in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Do age and performance status matter? A systematic review and network meta-analysis of immunotherapy studies in untreated advanced/metastatic non-oncogene addicted NSCLC.Frontiers in immunology · 2025Pooled it
- The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials.World journal of surgical oncology · 2021Pooled it
- Association Between Efficacy of Immune Checkpoint Inhibitors and Sex: An Updated Meta-Analysis on 21 Trials and 12,675 Non-Small Cell Lung Cancer Patients.Frontiers in oncology · 2021Pooled it
- Analysis of Prognosis and Immune Microenvironment of Protein Kinase C Substrate 80K-H in Diabetic Lung Cancer Patients.World journal of oncology · 2026Article
- Review
- The Impact of Age on the Effectiveness of Immune Checkpoint Inhibitors Therapy in Patients with Metastatic Non-Small-Cell Lung Cancer.Geriatrics (Basel, Switzerland) · 2025Article
- KLRD1 (CD94): A Prognostic Biomarker and Therapeutic Candidate in Head and Neck Squamous Cell Carcinoma.Journal of Cancer · 2025Article
- Article
- Immunotherapy in Older Patients with Cancer: A Narrative Review.International journal of general medicine · 2024Review
- Article
- Immune Checkpoint Inhibitors in "Special" NSCLC Populations: A Viable Approach?International journal of molecular sciences · 2023Review
- The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer.Cancers · 2023Review
- Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology.The oncologist · 2022Review
- Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer.Expert review of anticancer therapy · 2022Review
- Large-Scale Single-Cell and Bulk Sequencing Analyses Reveal the Prognostic Value and Immune Aspects of CD147 in Pan-Cancer.Frontiers in immunology · 2022Article
- Prognostic impact of chronological age on efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: Real-world data from 86 173 patients.Thoracic cancer · 2021Article
- Influence of Different Age Cutoff Points on the Prediction of Prognosis of Cancer Patients Receiving ICIs and Potential Mechanistic Exploration.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.